Added benefit of Empliciti combo in multiple myeloma not proven, says IQWiG

3 September 2016
2019_biotech_test_vial_discovery_big

In an early benefit assessment, the German Institute for Quality and Efficiency in Health Care (IQWiG) has now examined whether patients treated for multiple myeloma with the monoclonal antibody Empliciti (elotuzumab) in combination with lenalidomide (Revlimid) and dexamethasone who have received one previous treatment benefit from this new combination.

Empliciti, co-developed by US drugmakers Bristol-Myers Squibb (NYSE: BMY) and AbbVie (NYSE: ABBV), was approved for marketing in Europe in May this year.

Since the only study submitted by the drug manufacturer was unsuitable for answering this research question because the dosage of a comparator drug was too low, it was concluded that an added benefit of the new combination therapy in comparison with the appropriate comparator therapy is not proven.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology